Annual EBIT
-$304.33 M
+$34.92 M+10.29%
31 December 2023
Summary:
Revance Therapeutics annual earnings before interest & taxes is currently -$304.33 million, with the most recent change of +$34.92 million (+10.29%) on 31 December 2023. During the last 3 years, it has fallen by -$29.29 million (-10.65%). RVNC annual EBIT is now -1024.11% below its all-time high of -$25.09 million.RVNC EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$29.88 M
+$1.91 M+6.00%
30 September 2024
Summary:
Revance Therapeutics quarterly earnings before interest & taxes is currently -$29.88 million, with the most recent change of +$1.91 million (+6.00%) on 30 September 2024. Over the past year, it has increased by +$142.62 million (+82.68%). RVNC quarterly EBIT is now -2406.96% below its all-time high of -$1.19 million, reached on 31 December 2012.RVNC Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$278.45 M
+$4.17 M+1.48%
30 September 2024
Summary:
Revance Therapeutics TTM earnings before interest & taxes is currently -$278.45 million, with the most recent change of +$4.17 million (+1.48%) on 30 September 2024. Over the past year, it has increased by +$25.88 million (+8.50%). RVNC TTM EBIT is now -23259.73% below its all-time high of -$1.19 million, reached on 31 December 2012.RVNC TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +82.7% | +8.5% |
| 3 y3 years | -10.7% | +51.4% | -1.2% |
| 5 y5 years | -90.9% | +34.1% | -74.7% |
RVNC EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -10.7% | +10.3% | at high | +82.7% | -9.5% | +17.9% |
| 5 y | 5 years | -90.9% | +10.3% | at high | +82.7% | -74.7% | +17.9% |
| alltime | all time | -1024.1% | +10.3% | -2407.0% | +82.7% | <-9999.0% | +17.9% |
Revance Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$29.88 M(-6.0%) | -$278.45 M(-1.5%) |
| June 2024 | - | -$31.79 M(-28.2%) | -$282.62 M(-7.2%) |
| Mar 2024 | - | -$44.27 M(-74.3%) | -$304.63 M(+0.1%) |
| Dec 2023 | -$304.33 M(-10.3%) | -$172.51 M(+406.6%) | -$304.33 M(+11.1%) |
| Sept 2023 | - | -$34.05 M(-36.7%) | -$274.02 M(-13.6%) |
| June 2023 | - | -$53.80 M(+22.3%) | -$317.05 M(-1.2%) |
| Mar 2023 | - | -$43.97 M(-69.1%) | -$320.81 M(-5.4%) |
| Dec 2022 | -$339.25 M(+23.3%) | -$142.20 M(+84.5%) | -$339.25 M(+31.2%) |
| Sept 2022 | - | -$77.08 M(+33.9%) | -$258.57 M(+1.7%) |
| June 2022 | - | -$57.56 M(-7.8%) | -$254.30 M(-4.9%) |
| Mar 2022 | - | -$62.41 M(+1.4%) | -$267.37 M(-2.8%) |
| Dec 2021 | -$275.04 M(+2.0%) | -$61.52 M(-15.5%) | -$275.04 M(-5.2%) |
| Sept 2021 | - | -$72.81 M(+3.1%) | -$290.13 M(-1.4%) |
| June 2021 | - | -$70.63 M(+0.8%) | -$294.25 M(+5.1%) |
| Mar 2021 | - | -$70.08 M(-8.5%) | -$279.95 M(+3.9%) |
| Dec 2020 | -$269.56 M(+69.1%) | -$76.62 M(-0.4%) | -$269.56 M(+13.1%) |
| Sept 2020 | - | -$76.92 M(+36.5%) | -$238.27 M(+17.5%) |
| June 2020 | - | -$56.33 M(-5.6%) | -$202.75 M(+10.3%) |
| Mar 2020 | - | -$59.69 M(+31.7%) | -$183.81 M(+15.3%) |
| Dec 2019 | -$159.43 M(+14.3%) | -$45.33 M(+9.5%) | -$159.43 M(+5.1%) |
| Sept 2019 | - | -$41.41 M(+10.7%) | -$151.72 M(+6.0%) |
| June 2019 | - | -$37.39 M(+5.9%) | -$143.14 M(+2.4%) |
| Mar 2019 | - | -$35.30 M(-6.1%) | -$139.83 M(+0.2%) |
| Dec 2018 | -$139.52 M | -$37.62 M(+14.6%) | -$139.52 M(+1.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$32.83 M(-3.7%) | -$137.80 M(+1.7%) |
| June 2018 | - | -$34.08 M(-2.6%) | -$135.51 M(+5.7%) |
| Mar 2018 | - | -$34.99 M(-2.5%) | -$128.16 M(+6.7%) |
| Dec 2017 | -$120.13 M(+36.2%) | -$35.89 M(+17.5%) | -$120.13 M(+8.4%) |
| Sept 2017 | - | -$30.55 M(+14.3%) | -$110.82 M(+13.1%) |
| June 2017 | - | -$26.73 M(-0.9%) | -$98.00 M(+2.5%) |
| Mar 2017 | - | -$26.96 M(+1.5%) | -$95.58 M(+8.4%) |
| Dec 2016 | -$88.19 M(+22.0%) | -$26.58 M(+50.0%) | -$88.19 M(+5.8%) |
| Sept 2016 | - | -$17.72 M(-27.1%) | -$83.35 M(-1.3%) |
| June 2016 | - | -$24.32 M(+24.2%) | -$84.41 M(+10.2%) |
| Mar 2016 | - | -$19.57 M(-10.0%) | -$76.62 M(+6.0%) |
| Dec 2015 | -$72.29 M(+38.4%) | -$21.74 M(+15.7%) | -$72.29 M(+12.2%) |
| Sept 2015 | - | -$18.79 M(+13.7%) | -$64.42 M(+8.5%) |
| June 2015 | - | -$16.53 M(+8.5%) | -$59.39 M(+6.2%) |
| Mar 2015 | - | -$15.24 M(+9.8%) | -$55.90 M(+7.0%) |
| Dec 2014 | -$52.24 M(+40.1%) | -$13.88 M(+0.9%) | -$52.24 M(+11.8%) |
| Sept 2014 | - | -$13.75 M(+5.5%) | -$46.75 M(+12.6%) |
| June 2014 | - | -$13.04 M(+12.5%) | -$41.53 M(+4.3%) |
| Mar 2014 | - | -$11.59 M(+38.2%) | -$39.84 M(+6.8%) |
| Dec 2013 | -$37.28 M(+27.2%) | -$8.38 M(-1.8%) | -$37.28 M(+23.9%) |
| Sept 2013 | - | -$8.53 M(-24.8%) | -$30.10 M(+39.6%) |
| June 2013 | - | -$11.34 M(+25.5%) | -$21.56 M(+110.9%) |
| Mar 2013 | - | -$9.03 M(+657.8%) | -$10.22 M(+757.8%) |
| Dec 2012 | -$29.30 M(+8.2%) | -$1.19 M | -$1.19 M |
| Dec 2011 | -$27.07 M | - | - |
FAQ
- What is Revance Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Revance Therapeutics?
- What is Revance Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Revance Therapeutics?
- What is Revance Therapeutics quarterly EBIT year-on-year change?
- What is Revance Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Revance Therapeutics?
- What is Revance Therapeutics TTM EBIT year-on-year change?
What is Revance Therapeutics annual earnings before interest & taxes?
The current annual EBIT of RVNC is -$304.33 M
What is the all time high annual EBIT for Revance Therapeutics?
Revance Therapeutics all-time high annual earnings before interest & taxes is -$25.09 M
What is Revance Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of RVNC is -$29.88 M
What is the all time high quarterly EBIT for Revance Therapeutics?
Revance Therapeutics all-time high quarterly earnings before interest & taxes is -$1.19 M
What is Revance Therapeutics quarterly EBIT year-on-year change?
Over the past year, RVNC quarterly earnings before interest & taxes has changed by +$142.62 M (+82.68%)
What is Revance Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of RVNC is -$278.45 M
What is the all time high TTM EBIT for Revance Therapeutics?
Revance Therapeutics all-time high TTM earnings before interest & taxes is -$1.19 M
What is Revance Therapeutics TTM EBIT year-on-year change?
Over the past year, RVNC TTM earnings before interest & taxes has changed by +$25.88 M (+8.50%)